A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...
Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup ...
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results